Non-melanoma skin cancers (NMSC), comprising squamous cell (SCC) and basal cell carcinomas (BCC), have a significant impact upon the health care system because their overall incidence is higher than for all other cancers combined. Therefore, while not usually fatal, these skin carcinomas incur a very high cost for their management, e.g., 90% of the cost of treating breast cancer. The current standard of care is surgical excision with wide margins. Major morbidity stems from fibrosis, scarring, and loss of function after treatment. Photodynamic therapy (PDT) using 5-aminotevulinicacid (ALA) represents a non-disfiguring alternative to surgery, especially for patients with multiple tumors and for tumors in delicate sites. Currently, the efficacy of ALA-PDT is not adequate to realistically compete with surgery in the U.S.A. Based on one of the Program themes of Combination Photodynamic Biologic Therapy (CPBT), in Project 1, our overall hypothesis is that tumor-differentiating agents can be used to improve the efficacy of ALA-PDT so that PDT becomes a viable alternative to surgery for NMSC. Wewill build upon our discovery that two small molecules, methotrexate (MTX) and vitamin D (Vit D), can increase tumor cell differentiation and at the same time increase the levels of photosensitizer (PplX) within the cells, thus enhancing responsiveness to therapy. The project is translational in nature, with clinical and basic science components.
Aim 1 is preclinical, and uses mouse models of SCC and BCC to determine optimal dosing regimens for the systemic differentiating agent.
Aims 2 and 3 are clinical studies to determine the efficacy of topical Vit D and oral MTXas combination agents with ALA-PDT.
These Aims will also test new in vivo multimodal subsurface imaging devices for PplX detection, and evaluate C/EBP transcription factors ex vivo as prognostic markers of tumor response.
Aim 4 consists of mechanistic experiments that will examine regulatory functions and the prognostic value of the C/EBPs in terms of PplX accumulation, using the preclinical models and examining tissue-banked skin tumor specimens from the clinical studies.
Aim 4 is significant because those experiments will contribute to further improvements in the treatment design. The project involves significant collaborations with Project 4, Core B, and Core C of the Program. In summary, the potentialbenefits to public health will be the development of new rational combination approaches for PDT of skin cancer that include the manipulation of tumor cell physiology to increase endogenous levels of PplX. This will be coupled with individualized treatment planning based upon advanced PplX dosimetry and measurement of differentiation-responsive molecular markers, to optimize treatment response.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Massachusetts General Hospital
United States
Zip Code
Bulin, Anne-Laure; Broekgaarden, Mans; Hasan, Tayyaba (2017) Comprehensive high-throughput image analysis for therapeutic efficacy of architecturally complex heterotypic organoids. Sci Rep 7:16645
de Souza, Ana Luiza Ribeiro; LaRochelle, Ethan; Marra, Kayla et al. (2017) Assessing daylight & low-dose rate photodynamic therapy efficacy, using biomarkers of photophysical, biochemical and biological damage metrics in situ. Photodiagnosis Photodyn Ther 20:227-233
Wang, Hexuan; Nieskoski, Michael D; Marra, Kayla et al. (2017) Elastographic Assessment of Xenograft Pancreatic Tumors. Ultrasound Med Biol 43:2891-2903
Nieskoski, Michael D; Marra, Kayla; Gunn, Jason R et al. (2017) Collagen Complexity Spatially Defines Microregions of Total Tissue Pressure in Pancreatic Cancer. Sci Rep 7:10093
Pereira, S P; Goodchild, G; Webster, G J M (2017) The endoscopist and malignant and non-malignant biliary obstruction. Biochim Biophys Acta :
Obaid, Girgis; Spring, Bryan Q; Bano, Shazia et al. (2017) Activatable clinical fluorophore-quencher antibody pairs as dual molecular probes for the enhanced specificity of image-guided surgery. J Biomed Opt 22:1-6
Mlacker, Stephanie; Kaw, Urvashi; Maytin, Edward V (2017) Use of photodynamic therapy and acitretin in generalized eruptive keratoacanthoma of Grzybowski. JAAD Case Rep 3:457-459
Anand, Sanjay; Rollakanti, Kishore R; Brankov, Nikoleta et al. (2017) Fluorouracil Enhances Photodynamic Therapy of Squamous Cell Carcinoma via a p53-Independent Mechanism that Increases Protoporphyrin IX levels and Tumor Cell Death. Mol Cancer Ther 16:1092-1101
Keane, Margaret G; Shah, Amar; Pereira, Stephen P et al. (2017) Novel biomarkers and endoscopic techniques for diagnosing pancreaticobiliary malignancy. F1000Res 6:1643
Lee, Han Hee; Choi, Myung-Gyu; Hasan, Tayyaba (2017) Application of photodynamic therapy in gastrointestinal disorders: an outdated or re-emerging technique? Korean J Intern Med 32:1-10

Showing the most recent 10 out of 163 publications